Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous NKTR-358 in Patients With Systemic Lupus Erythematosus

Next Previous
Trial Profile

A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous NKTR-358 in Patients With Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezpegaldesleukin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 04 Nov 2020 Results published in the Nektar Therapeutics Media Release.
    • 04 Nov 2020 According to a Nektar Therapeutics media release, additional clinical data from this trial presented at at 2020 American College of Rheumatology (ACR) Congress. The company will host a call today for analysts and investors to review this data.
    • 29 Oct 2020 According to a Nektar Therapeutics media release, the company will webcast an analyst and investor conference call at ACR 2020 on 4th Nov 2020 at 4:15 p.m. EST. The event will follow virtual release by ACR of the poster presentation of data from this study. The poster will be displayed online from 4th Nov, 2020 to 11th Mar 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top